{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:43:03Z","timestamp":1790419383244,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,5]],"date-time":"2017-02-05T00:00:00Z","timestamp":1486252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","onlinejacc.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jacc.2016.12.038","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T14:16:33Z","timestamp":1489414593000},"page":"1363-1371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Non\u2013Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease"],"prefix":"10.1016","volume":"69","author":[{"given":"Giulia","family":"Renda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.12.038_bib1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.12.038_bib2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.cjca.2014.03.022","article-title":"Epidemiology of acquired valvular heart disease","volume":"30","author":"Iung","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2016.12.038_bib3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: a population-based study","volume":"368","author":"Nkomo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.12.038_bib4","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u201cvalvular\u201d atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.12.038_bib5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1161\/01.STR.19.8.937","article-title":"Atrial fibrillation and stroke: new ideas, persisting dilemmas","volume":"19","author":"Halperin","year":"1988","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2016.12.038_bib6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.12.038_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.12.038_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.12.038_bib9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.12.038_bib10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2016.12.038_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.12.038_bib12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cjca.2014.08.001","article-title":"2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2016.12.038_bib13","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.12.038_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.12.038_bib15","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native\u00a0mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.12.038_bib16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.12.038_bib17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"69","author":"De Caterina","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.12.038_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/003335490712200301","article-title":"Epidemiology and education: using public health for teaching mathematics and science","volume":"122","author":"Stroup","year":"2007","journal-title":"Public Health Rep"},{"key":"10.1016\/j.jacc.2016.12.038_bib19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jacc.2016.12.038_bib20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.12.038_bib21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.12.038_bib22","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.12.038_bib23","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/MD.0000000000000336","article-title":"Obstructive sleep apnea and serious adverse outcomes in patients with cardiovascular or cerebrovascular disease: a PRISMA-compliant systematic review and meta-analysis","volume":"93","author":"Xie","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.jacc.2016.12.038_bib24","series-title":"Introduction to Meta-Analysis","first-page":"171","article-title":"Subgroup analyses","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.jacc.2016.12.038_bib25","first-page":"1","article-title":"The jackknife \u2014 a review","volume":"61","author":"Miller","year":"1974","journal-title":"Biometrika"},{"key":"10.1016\/j.jacc.2016.12.038_bib26","unstructured":"Higgins J, Altman D, Sterne J. Chapter 8: Assessing Risk of Bias in Included Studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. (Updated March 2011). The Cochrane Collaboration. Available at: handbook.cochrane.org. Accessed April\u00a010, 2016."},{"key":"10.1016\/j.jacc.2016.12.038_bib27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/heartjnl-2015-308120","article-title":"Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban","volume":"102","author":"Breithardt","year":"2016","journal-title":"Heart"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717303443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717303443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:30:17Z","timestamp":1549002617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109717303443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0735109717303443"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.12.038","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727420612.793535283","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non\u2013Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}